These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 21673461)
1. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET). Inoue T; Ikeda H; Nakamura T; Abe S; Taguchi I; Kikuchi M; Toyoda S; Miyazono M; Kishi T; Sanai T; Node K Intern Med; 2011; 50(12):1273-8. PubMed ID: 21673461 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Yasuda G; Kuji T; Hasegawa K; Ogawa N; Shimura G; Ando D; Umemura S Ren Fail; 2004 Jul; 26(4):411-8. PubMed ID: 15462110 [TBL] [Abstract][Full Text] [Related]
3. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547 [TBL] [Abstract][Full Text] [Related]
4. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Ueda S; Fukami K; Okuda S; Yamagishi S Pharmacol Res; 2010 Jan; 61(1):58-61. PubMed ID: 19666118 [TBL] [Abstract][Full Text] [Related]
5. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial. Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909 [TBL] [Abstract][Full Text] [Related]
11. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Lintott CJ; Scott RS; Bremer JM; Shand BI Am J Cardiol; 1995 Jul; 76(2):97A-101A. PubMed ID: 7604809 [TBL] [Abstract][Full Text] [Related]
12. Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Di Lullo L; Addesse R; Comegna C; Firmi G; Galderisi C; Iannacci GR; Polito P Adv Ther; 2005; 22(6):601-12. PubMed ID: 16510377 [TBL] [Abstract][Full Text] [Related]
13. Impact of fluvastatin on hyperlipidemia after renal transplantation. Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777 [TBL] [Abstract][Full Text] [Related]
14. Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease. Abe M; Maruyama N; Oikawa O; Maruyama T; Okada K; Soma M Scand J Clin Lab Invest; 2015 Sep; 75(5):421-7. PubMed ID: 26067610 [TBL] [Abstract][Full Text] [Related]
15. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial. Ueshima K; Kasahara M; Koya D; Babazono T; Sato T; Imamoto M; Yasuno S; Fujimoto A; Tanaka S; Kimura G; Nakao K Clin Exp Nephrol; 2013 Apr; 17(2):211-7. PubMed ID: 22948416 [TBL] [Abstract][Full Text] [Related]
16. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics. Fauler G; Abletshauser C; Erwa W; Löser R; Witschital K; März W Int J Clin Pharmacol Ther; 2007 Jun; 45(6):328-34. PubMed ID: 17595890 [TBL] [Abstract][Full Text] [Related]